SANTEN-PHARMACEUTICAL
26.7.2021 09:02:06 CEST | Business Wire | Press release
Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to implement United Nations General Assembly Resolution A/75/L.108 on eye health. This comes after several months of collaboration with the IAPB, advocating for global action to improve access to basic eye health services.
Santen is committed to reducing the loss of social and economic opportunities for people living with eye conditions. The new UN General Assembly resolution encourages governments and key stakeholders from around the world to mobilize the necessary resources to address this urgent priority. UN entities including UNICEF, UN-Women, UNDP, UNESCO, the International Labor Organization and the UN Road Safety Collaboration will work to promote and include eye health in their work. International financial institutions and donors will be urged to include eye health priorities in their funding programs. We take the adoption of this resolution as an opportunity to further enhance our policy and advocacy activities with the IAPB.
“The eye health sector has believed for a long time that quality eye care is critical to the world achieving the Sustainable Development Goals” said Peter Holland, CEO of IAPB. “IAPB and its members are committed to supporting governments to implement this resolution and ensure that no one is left behind”.
To support the implementation of this resolution, Santen and the IAPB will work together on a number of initiatives as part of their ongoing strategic partnership , including:
- Partnership with national governments and supranational stakeholders to establish an effective monitoring system and encourage the inclusion of eye health in voluntary national reporting on the Sustainable Development Goals (SDGs).
- Coordination of an advocacy and public affairs strategy to lobby for the inclusion of two eye health targets in the next review of the SDGs by the UN Inter-Agency Expert Group in 2025.
Today, 1.1 billion people are living with preventable sight loss due to a lack of access to basic eye care services. With appropriate allocation of resources and investment for the early detection and treatment of eye conditions, including disease awareness campaigns and regular eye tests, sight can be protected.1 Vision loss can have a significant detrimental impact on quality of life (QOL), including depression, discomfort and social isolation. Improving access to eye care services therefore, has the potential to improve the QOL for millions of people.2 Additionally, sight loss is calculated to cost the global economy $411bn in productivity each year, showing it has tremendous economic consequences3 . Eye health is directly linked to more than half of the sustainable development goals (SDGs), including eliminating poverty and hunger, improving education, and gender equality4 . Therefore, a “whole of government approach” to eye care and strengthened collaboration between stakeholders is necessary to ensure the people living with preventable sight loss receive access to support and treatment.
“The adoption of UN resolution on eye health represents a major leap towards the realization of our WORLD VISION (Happiness with Vision)” said Shigeo Taniuchi, President & CEO of Santen, “There is ample evidence that eye health is a global development issue. About 90% of preventable vision loss occurs in low and middle income countries, of which 55% affects women and girls. People, in general, receive 80% of information visually and eye disease tend to be chronic, affecting patients’ quality of life. As a specialized company dedicated to ophthalmology, we are committed to promoting international efforts on eye health and contributing to the realization of the SDGs. Supporting the implementation of this resolution is a crucial step towards facilitating access to eye care services and reducing the loss of social and economic opportunities for people around the world due to eye conditions”.
References:
- International Agency for the Prevention of Blindness (IAPB). Vision Atlas. Available here: https://www.iapb.org/learn/vision-atlas
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
About Santen
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.
Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.
With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen’s website (www.santen.com
).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005246/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Iconic Landmark Danjiang Bridge Opened to Redefine Taiwan18.5.2026 12:02:00 CEST | Press release
The Danjiang Bridge, one of Taiwan’s most significant recent public infrastructure projects, officially opened with a series of large-scale public events, transforming the bridge into a new cultural landmark and civic space. The program featured the “Danjiang Bridge Together Arts Festival,” immersive public activities, and a special performance of Light Chain by Cloud Gate Dance Theatre, symbolizing the integration of architecture, engineering, and the arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517667930/en/ The Danjiang Bridge is an iconic landmark in Taiwan with global recognition. (Photo via Highway Bureau , Motc) Spanning the mouth of the Tamsui River, the bridge serves as both a major transportation project and a recognizable architectural landmark, establishing a new urban symbol for Taiwan. Designed by Zaha Hadid Architects, the project gained international attention throughout its development and was sel
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
